

***Fiscal Year 2024 Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Idea Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT942524DMDRPIDA</a></p>	<p><b><i>Established Investigators:</i></b> Independent investigators at or above the level of Assistant Professor (or equivalent); <b><i>or</i></b></p> <p><b><i>New Investigator – Early Stage:</i></b> Investigators that meet the following criteria by the application submission deadline date:</p> <ul style="list-style-type: none"> <li>• Have not previously received a DMDRP Idea Development Award</li> <li>• Are <b>within 10 years</b> of first faculty appointment (or equivalent)</li> </ul> <p><b><i>New Investigator – Transitioning:</i></b> Investigators in an area other than muscular dystrophy at or above the level of Assistant Professor (or equivalent) seeking to transition to a career in Duchenne muscular dystrophy (DMD), thereby bringing their expertise to the field.</p> <ul style="list-style-type: none"> <li>• Must pursue an active line of research in DMD and commit at least 10% of their efforts during each budget year toward the proposed DMD research project.</li> </ul>	<ul style="list-style-type: none"> <li>• Supports the development of innovative, high-impact ideas that advance the understanding of DMD and ultimately lead to improved outcomes.</li> <li>• Must address opportunities and challenges in the development of safe and effective therapies that address primary pathology of DMD. <b><i>Therapies that will be efficacious across the life span, particularly adolescence and adults are encouraged.</i></b></li> <li>• <b>Preliminary data are required.</b></li> <li>• Clinical trials or applications including a clinical trial aim are <b><i>not allowed.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$350,000</b> for direct costs (plus indirect costs).</li> <li>• The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 1, 2024 5:00 p.m. ET</p> <p><b>Application:</b> August 22, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical/Translational Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT942524DMDRPCTRA</a></p>	<p>Independent investigators at all career levels.</p> <p><b>Early-Career Partnering Principal Investigator (PI) Option:</b></p> <ul style="list-style-type: none"> <li>The Partnering PI must be an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission. Lapses in research time or appointments as denoted in the biographical sketch should be explained in the application.</li> <li>It is encouraged, but not required, that the partnering PI is a clinician or clinical scientist (M.D. or M.D./Ph.D.) to increase collaboration between clinical and nonclinical aspects of DMD research.</li> </ul>	<ul style="list-style-type: none"> <li>Supports translational studies that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic.</li> <li>Research projects investigating therapies that will be efficacious across the life span, particularly in adolescents and adults, are strongly encouraged.</li> <li>Preliminary data required.</li> <li>Clinical trials are allowed.</li> <li>NEW FOR FY24: Different funding levels, based on the scope of research, are available. It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.</li> </ul> <p>The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:</p> <ul style="list-style-type: none"> <li>Funding Level 1: Supports smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed.</li> <li>Funding Level 2: Research Level 2 is intended to support larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed.</li> </ul>	<p>Funding Level 1</p> <ul style="list-style-type: none"> <li>Maximum funding of \$650,000 for direct costs (plus indirect costs).</li> <li>Maximum period of performance is 3 years.</li> </ul> <p>Funding Level 2</p> <ul style="list-style-type: none"> <li>Maximum funding of \$1,350,000 in direct costs (plus indirect costs).</li> <li>Maximum period of performance is 4 years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 1, 2024 5:00 p.m. ET</p> <p><b>Application:</b> August 22, 2024 11:59 p.m. ET</p>